13 January 2025
13 January 2025
IDRx’s lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal tumours.
The deal would be the biggest biotech transaction in more than a year.
Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.
Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.
Mediar will receive a combined $99m consisting of an upfront payment and near-term milestones.
Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.
The company has three clinical CAR-T programmes backed by its precision-targeting cellular system Imod platform technology.
Under the agreement, Mabworks will obtain an upfront cash payment of $9m from Climb Bio.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest report examines the business environment, challenges and trends that are going to impact the biopharmaceutical industry in 2025. Anti-obesity medications, IO drug development, and increasing costs of clinical trials will be among the most impactful industry trends for the next 12 months. Oncology will dominate the therapy landscape in 2025, but dermatology will display the highest growth.
GlobalData's latest report examines the business environment, challenges and trends that are going to impact the biopharmaceutical industry in 2025. Anti-obesity medications, IO drug development, and increasing costs of clinical trials will be among the most impactful industry trends for the next 12 months. Oncology will dominate the therapy landscape in 2025, but dermatology will display the highest growth.
GlobalData's latest report examines the business environment, challenges and trends that are going to impact the biopharmaceutical industry in 2025. Anti-obesity medications, IO drug development, and increasing costs of clinical trials will be among the most impactful industry trends for the next 12 months. Oncology will dominate the therapy landscape in 2025, but dermatology will display the highest growth.
Give your business an edge with our leading industry insights.
